|
Download Annual Meeting Brochure
Speaker Biographies
Meeting Committee
Meeting Program:
 Partnering Meetings
Registration:
Sponsors:
Tech Fair
Sign up for the LES Member Cabaret
Apply for a spot in the LES Band
Miscellaneous Info
|
Speaker Biographies (Updated 10/14/04)
Irene Abrams
Irene Abrams is a Technology Licensing Officer at the M.I.T. Technology Licensing Office. She is a graduate of the University of Pennsylvania and The Johns Hopkins University and has done graduate studies at M.I.T. Irene specializes in licensing biotechnology patents on behalf of M.I.T. and the Whitehead Institute. She often speaks on university technology licensing issues.
Steven Adam
Mr. Adam has global responsibility for Chipworks' revenue generation, and has more than 16 years of experience working in Sales, Business Development, Licensing and Strategic Alliances. Prior to joining Chipworks, Mr. Adam worked at Ottawa-based Corel Corp. licensing WordPerfect to PC manufacturers, before joining two separate start-up software companies in a business development management capacity. Mr. Adam has been a member of LES for 3 years, is has been serving co-chair of the Semiconductor Sub-Committee of the High Tech Sector for the past 2 years. Mr. Adam has presented at LES events in Ottawa, Toronto and hosted a Workshop at the 2003 Annual Meeting in San Diego.
Nermien Al-Ali
Nermien is an adjunct professor Franklin Pierce Law Center and the Head of the Intellectual Property Department of Ibrachy & Dermarkar in Egypt. She obtained her law degree from Sydney University, Australia, and practiced four years in Sydney before moving to Cairo. She obtained her Masters of Law in Intellectual Property from Franklin Pierce Law Center, where she worked as a Research Professor to continue her research, teach and write a book on the latest business models for managing intellectual property as business assets. Her book - Comprehensive Intellectual Capital Management: Step-by-Step, John Wiley, New York 2003 - is acclaimed by leading academic and business figures, including Professor Robert Harrison of George Mason University Business School, and David Near, Director of Business Excellence of Dow Chemical (U.S.A).
Daniel Alderman
Dan Alderman is an Intellectual Capital Manager for the Dow Chemical Company and is a member of the Global ICM Leadership Team. He is responsible for Intellectual Capital Management for Corporate Research, Manufacturing & Engineering, Licensing, Hydrocarbons & Energy and Chemicals & Intermediates. Dan is a Chemical Engineer by training and has managed intellectual capital for the past four years. His 30 year career at Dow has included a variety of positions in business, research and technical services.
Joseph P. Allen
Joseph P. Allen has been a prominent figure in the development of technology transfer in the United States. A 20-year veteran of national efforts to put federally developed cutting-edge technology in the hands of U.S. industry, Allen has served as President of the Robert C. Byrd National Technology Transfer Center (NTTC) at Wheeling Jesuit University since October 1997.
Allen was the instrumental U.S. Senate staffer securing passage of legislation opening up U.S. universities for R&D partnerships with U.S. industry. This legislation, the Bayh-Dole Act of 1980, has enabled the high degree of university/industry cooperation in the U.S.
In addition, Allen worked as a key negotiator in several international agreements, including the U.S.-Japan Science and Technology Agreement, which brought U.S. international science and technology agreements into line with domestic technology transfer policies. Allen was also co-founder of the Association for Federal Technology Transfer Excellence, and served for a time as the Association's President.
Allen came to NTTC in 1992 from the U.S. Department of Commerce, where he served as the Director of the Office of Technology Commercialization. He was instrumental in the passage of major commercialization laws, including the Federal Technology Transfer Act and the 1989 National Technology Transfer Competitiveness Act, allowing U.S. industry to perform joint research and development with federal laboratories. Allen's office at DOC oversaw the implementation of those laws as well as those allowing universities to license patentable technologies to U.S. industry. Allen also testified and was involved in passage of the Technology Transfer Commercialization of 1999.
At NTTC, Allen oversees the numerous services offered by NTTC to federal agencies and private companies. He not only worked to create the Market and Technology Assessment unit, now one of NTTC's most sought-after service areas, but he also worked to shape the Training and Professional Development and Planning and Development offices. Allen also co-authored Technology Transfer for Entrepreneurs, published by Praeger Press.
Beth Arnold
Beth Arnold is a Partner in Foley Hoag's Boston office. For over 15 years, her practice has focused on obtaining worldwide patent protection on drug products and drug discovery technologies for innovative biotechnology and pharmaceutical companies and research institutions. She also performs patent due diligence in connection with corporate financings and corporate or product line acquisitions and mergers. She renders clearance, non-infringement and invalidity opinions and negotiates and drafts a variety of research, development and license agreements. Ms. Arnold was formerly an in-house patent counsel at Genzyme Corporation and a pharmaceutical researcher. She received a B.S. (cum laude, 1983) in biology from the University of Rhode Island, a M.S. (cum laude, 1986) in molecular biology from Boston University and a J.D. from Northeastern University.
Caroline Baker
Caroline S.A. Baker is a Technology Marketing Specialist with the Maryland Department of Business and Economic Development (DBED) in the Division of Technology Strategy and Business Development. She brings extensive business experience to her work with the state, including six years of management experience in high-growth technology companies.
For DBED, Ms. Baker is responsible for promoting the State of Maryland as a center of business and technology innovation and finding new ways to effectively leverage Maryland's wealth of technology assets for economic growth. Her expertise includes business incubation, business strategy, cluster development, technology transfer and technology-based economic development.
Prior to working with DBED, Ms. Baker led several entrepreneurial businesses, including her own consulting firm, where she advised clients on all aspects of business and marketing strategy including competitive analysis, market research, strategic planning, and product design and positioning. Ms. Baker has held management positions in a number of technology-based businesses-including LaunchFuel, a consulting firm for technology startups; AmericasDoctor.com, a healthcare information portal; and Magnet Interactive, a high-end interactive agency, where she worked with clients such as the Kellogg Company.
Earlier in her career, Ms. Baker served on the management team of IntraACTIVE, an intranet software company, where her responsibilities included marketing, business development, and product management. During her tenure at IntraACTIVE, Ms. Baker directed a major upgrade of the company's core product, InTandem, which was later acquired by Mail.com for $14M.
Ms. Baker holds a Bachelor of Arts degree with honors in English from Wesleyan University in Middletown, Connecticut, and studied at St. Catherine's College, Oxford University in Oxford, England.
Deborah Day Barbara
Deborah Day Barbara, M.B.A. is the Senior Director of Technology Development for Licensing and Technology Development at The Johns Hopkins University. A position she has held since March 2001. Ms. Barbara received a B.S. in Biochemistry and Molecular Biology from the University of Maryland, performed post-graduate research in Cell Biology and received a Masters of Business Administration degree from Loyola College in Maryland. In 1987 she left the laboratory to join Amersham Life Sciences. Ms. Barbara spent 11 1/2 years with Amersham Life Sciences in variety of sales, marketing and technology transfer positions. In 1998 she joined the Johns Hopkins University as Director for Technology and Corporate Initiatives in the Department of Pathology. In this role she was responsible for all aspects of the Department's interactions with industry including the drafting and negotiation of licenses, collaborations and sponsored research agreements and the solicitation of unrestricted grants to support the departmental research and technology development initiatives.
Phillip Barnett
Phillip Barnett is a Director in the PwC Intellectual Assets Management (IAM) practice, Chicago. He assists clients in all aspects of the design and implementation of Holistic¨ IAM processes emphasizing shareholder value creation and effective intangible asset management. Prior to joining PwC, Phil worked at The Dow Chemical Company where as a founding designer of Dow's IAM program, he lead the creation of new corporate-wide IA management processes including IA classification, internal benchmarking, trade secrets management, IA value accounting, and new development pipeline systems. His management experience includes global IA manager for Dow's 2 largest specialty plastics businesses, Epoxy Products and Polyurethanes.Ê
His technical experience included several years in research and new product development with Dow's largest customers in the fields of acrylic, epoxy, and polyurethane applications for automotive, marine, foams, packaging and architectural markets. Ê
Phil has recent PwC consulting project experieunce in the fields of down stream refining, biolubricant stabilization, polyurethane chemicals, dual functional monomers, plastics materials and packaging processes, advanced materials for microelectronics, software, and several automotive component technologies.
Phil is the chairman of E104 for LES USA-Canada, and has co-developed the Intellectual Asset Management module for PDS, and is a new Trustee of LES. He is also a Trustee of the Commercial Development and Marketing Association Educational Foundation, on the steering committee for the Chicago CDMA, and Meeting Chairman for the National Fall Meeting in 2004 in Chicago.
He received Bachelor and Master of Science degrees from Stephen F. Austin University .
Nila Bhakuni
Nila Bhakuni, BSME, MSME, MBA. Currently a Technology Transfer Officer for Harvard University with full responsibility for the physical sciences portfolio and software for the university. She has 5 years of experience in academic technology transfer also working at Carnegie Mellon University. Prior to that she worked for 10 years in research and development focusing on various areas of product design and commercialization for Alcoa, Inc. serving the container, automotive, and aerospace business units.
Jeffrey D. Bleil
Jeffrey D. Bleil is the Chief Technology Officer of UTEK Corporation (AMEX: UTK). UTEK is a technology transfer company, the mission of which is to find, acquire, and transfer new University and Laboratory technologies to its corporate clients. Dr Bleil founded and served as Chief Technology Officer of ZyGam, Inc., a Biotechnology Company. Dr. Bleil received his B.S. in Biological Chemistry from Lawrence University, Appleton, and a Ph.D. in Cell and Development Biology from Harvard Medical School, Boston. Dr. Bleil was a Postdoctoral Fellow at The Medical Research Council Laboratory of Molecular Biology in Cambridge, England and an Assistant Professor and Principle Investigator in the Department of Molecular Biology at The Scripps Research Institute, La Jolla.
Christopher Bloom
Christopher A. Bloom is a Member of the Intellectual Property Department at Bell, Boyd & Lloyd LLC, concentrating in biotechnology and information technology.
In nearly 30 years of practice, Mr. Bloom has counseled technology companies and academic institutions in strategies to develop, protect and enforce intellectual property rights.
In 1995, he led the team that prevailed in the landmark United States Supreme Court trademark case, Qualitex Company v. Jacobson Products Co., Inc. which determined that color alone could be a trademark.
Mr. Bloom is a member of the Intellectual Property Advisory Board of De Paul University School of Law. He is also a faculty member in the e-commerce program of DePaul University School of Computer Science, Telecommunications and Information Systems.
Mark Bloom
Mark G. Bloom, Esq. is Associate General Counsel and Chief Intellectual Property Counsel for The Cleveland Clinic Foundation (CCF).
Mr. Bloom received a Bachelor of Science Degree in Microbiology/Biochemistry from the Ohio State University and a Juris Doctor from Franklin Pierce Law Center. While at Franklin Pierce, he served as an Issue Editor of IDEA: The Journal of Law and Technology. Mr. Bloom is a member of four state bars and numerous federal courts and professional organizations and is registered to practice before the United States Patent and Trademark Office. Before attending law school, Mr. Bloom worked in sales and marketing for the pharmaceutical, medical device, and medical diagnostic software industries. After receiving his law degree, Mr. Bloom served as patent counsel for the Roswell Park Cancer Institute and as a marketing and legal consultant for Harvard Medical School's Funds for Discovery Program (a seed fund for biotech start-ups). Immediately prior to joining CCF, Mr. Bloom was employed as a Licensing Officer for the Wisconsin Alumni Research Foundation (WARF).
Mr. Bloom brings more than twenty years of corporate sales, marketing, and intellectual property law and management experience to CCF where his myriad responsibilities include overseeing the invention patenting process, facilitating industrially-sponsored research, out-licensing of CCF technologies, participating in the formation of new business entities based on CCF technologies, and serving as Special Counsel to The Cleveland Clinic Press.
The Cleveland Clinic Foundation (CCF), founded in 1921, integrates clinical and hospital care with research and education in a private, not-for-profit group practice. It is consistently ranked by U.S. News & World Report in the top four hospitals in America and has been ranked No. 1 in heart care for ten consecutive years. Approximately 1,900 full-time salaried physicians and scientists at CCF (Cleveland, OH Metro Area) and Cleveland Clinic Florida (Naples and Fort Lauderdale, FL) represent more than 100 medical specialties and subspecialties. In 2003, there were more than 2.65 million outpatient visits and 52,000 hospital admissions to CCF. Patients came for treatment from every state and from more than 90 countries. CCF's website address is www.clevelandclinic.org.
Sidney Blum
Sidney Blum is a Partner with KPMG's Contract Compliance Services (CCS) practice. Sid is globally recognized as a foremost leader and developer of modern royalty compliance services. His services are sought after by many leading companies as he is a renown speaker and developer in this unique area. As a 17 year veteran, he has served a range of licensors including the largest biotechnology, toy, entertainment and software companies resulting in findings in excess of $100 million. He is a CPA, Certified Fraud Examiner and Dipolamate with the American Board of Forensic Examiners. KPMG's practice includes a global network of firms and over 200 individuals dedicated to providing compliance services making KPMG one of the largest providers of CCS professionals. KPMG's contract professionals provide a wide range of services for various agreements such as royalty, favored nation, theatrical & video distribution, advertising agency, manufacturing, joint venture, etc. We also provide white papers, such as the recently published, "The Self-Reporting Economy: A Matter of Transparency and Trust." Sid can be contacted at sidneyblum@kpmg.com or at 818-227-6906.
David C. Bonner
Dr. David C. Bonner is President, Chief Operating Officer, and a member of the Board of Directors of Ideation International, Inc.(www.ideationtriz.com), and Managing Director of Intellectual Property Business International, LLC (www.ipbizint.com).
Dr. Bonner has had a career as an engineer, manager, and corporate officer, Chief Technology Officer of Cabot Corporation in Boston. He has served led organizations in technology, technology licensing, and engineering in the U.S., Europe, and Asia. He was also responsible for leading several start-up ventures as well as a global products business.
He is a graduate of the University of California, Berkeley, with a Ph.D. in chemical engineering; and the University of Texas at Austin with B.S.Ch.E. and M.S.Ch.E. degrees. He is a Registered Professional Engineer in Texas and was elected a Distinguished Engineering Graduate of the University of Texas in 2001.
Early in his career, he was an Associate Professor of Chemical Engineering at Texas A&M University, specializing in polymer systems.
He is widely published in various refereed technical journals and has been interviewed by business publications.
He served on various National Academy of Science and National Academy of Engineering Boards and Committees. He is currently Vice Chair of the U. S. National Committee for the International Union of Pure and Applied Chemistry and an at-large member of the National Institute of Standards and Technology Board of Assessors.
Dr. Bonner currently serves as Chair of the Rice University Chemical Engineering Advisory Board, Senior Member of the University of Texas Engineering Foundation Advisory Committee, the Engineering Committee of Visitors of Vanderbilt University, the Advancement Council of the University of Akron College of Polymer Science and Polymer Engineering, and the Chemical Engineering Advisory Board of Virginia Commonwealth University. Dr. Bonner also serves as a Director of Aexcel Corporation.
Gordon Bremer
As an electronics engineer, Research Fellow and R&D Director at Paradyne Corporation, Gordon has led fundamental research, championed, designed and managed many key data communications technology developments and successful product lines since 1974, the most recent of which is ReachDSLÒ, a high-performance DSL technology.
Gordon has 63 U.S. patents with another 25 pending in fields such as HDTV, data communications, simultaneous analog/data communications, voice band modems and DSL. He received the 1994 AT&T Harold S. Black Patent Recognition Award for Commercial Success.
Gordon was founding chairman of what is now the TIA TR30.1 standards committee and represented Paradyne at the ITU for over 15 years. He and his staff have contributed directly to G.992, V.90, V.34, V.61, V.8bis, V32, V33, V.27bis, V.37 and V54. They remain proactive in the ITU, T1E1, ETSI and the DSL Forum.
In 1980, Gordon launched the development of Paradyne's patent portfolio, and he continues to manage that development which has resulted in 340 U.S. patents with another 66 pending. The telecommunications patent portfolio was ranked 27th worldwide by MIT Technology Review in 2003. These patents address a diversified range of technologies: DSL, dial modems, HDTV, media gateways, frame relay, cellular, cable modems, fax, digital audio broadcasting, service level management and wireless, as examples. In late 2003, Gordon was asked to focus his attention on the portfolio, especially with regard to exploitation to benefit Paradyne's business. He is currently involved in patent out-licensing, patent sales and litigation.
Joseph Brindisi
Joseph J. Brindisi is General Counsel and Vice President of Business Development, Kyowa Pharmaceutical, Inc. and is responsible for helping define the globalization strategy for the pharmaceutical business and product pipeline of Kyowa. Joe has also worked with Kyowa Hakko to found a new U.S. incorporated and based Biotech Company called BioWa. BioWa is the exclusive licensee of a new-generation platform technology developed by Kyowa Hakko (i.e. Potelligent» Technology) that can maximize the value of therapeutic monoclonal antibodies (mAb) for BioWa and its Biotech partners.
Neil Brown
Neil L. Brown, Vice President Licensing & Acquisitions, ProSkelia. Following a post-doctoral fellowship at the University of Montpellier (France) Dr Brown entered the R&D division of Hoechst-Roussel (France) in 1977. He joined the Fournier Group (Dijon, France) as Director of Pharmacology in 1986, and became its Director of Licensing and Scientific Advisor some time later. In 1996 Dr Brown joined Debiopharm (Lausanne, Switzerland) as Vice President, and in 2000 became CEO of Debioclinic (Paris, France). Prior to joining ProSkelia Dr Brown was a consultant to the health-care industry, and cofounder and interim CEO of GeneSignal (France) and Pharminox (UK). Dr Brown has extensive experience in business development, licensing and drug development (incuding FDA and EMEA approvals). Dr Brown holds a BSc (Special Hons.) from the University of London (UK), an MSc and PhD, from the University of Wales (UK).
Richard Brudnick
Richard Brudnick is Director of Business Development at Biogen Idec Inc. He has led and successfully concluded product, portfolio, and M&A deals on both the ÒbuyÓ and ÒsellÓ sides with companies of diverse size having varied objectives. Prior to joining Biogen Idec he built, operated, bought, and sold a number of entrepreneurial ventures, and holds undergraduate and graduate degrees from the Massachusetts Institute of Technology.
Alice Burt
Alice G. Burt is Vice President, Legal and Intellectual Property
Transactions with BTG International Inc., the global technology transfer
and intellectual property commercialization company. Prior to joining
BTG in 2001, she was senior corporate counsel at Safeguard Scientifics,
Inc. for 14 years. She works primarily on venture-related transactions
for start-up and early stage companies and on the development and
licensing of intellectual property and technology. Alice received her
JD from the Law School of the University of Pennsylvania.
Diane Cabell
Diane Cabell is a fellow at the Berkman Center for Internet & Society at Harvard Law School where she has directed the Center's clinical programs for the past five years. She was a member of the first committee established by ICANN to review mechanisms for public participation in the organization that coordinates Internet protocols and assisted in setting up the first public election of ICANN directors.
Ms. Cabell has practiced technology law for 30 years. In addition to her clinical work, she currently advises the Open Knowledge Network (a P2P network of public domain and indigenous knowledge for southern nations), is a co-director of Chilling Effects (a project involving several law school clinics that investigates the use of cease & desist notices to suppress online speech) and serves as corporate counsel for Creative Commons Corporation (a non-profit corporation dedicated to protecting the public domain). Her bio is at http://cyber.law.harvard.edu/home/diane_cabell.
Richard Cahoon
Dr. Richard Cahoon holds undergraduate degrees in biology and political science and a Masters in bioprocess engineering. In the 1980's he founded a biotech start-up and was later a principal in a bioprocess engineering firm. In 1990, Dr. Cahoon joined Cornell Office's of Patents & Technology Marketing as Assistant Director. Prior to this, he was Associate Director of the Center for Bioprocess Engineering, an NSF National Engineering Research Center. In 1992, Dr. Cahoon was appointed Cornell's Associate Director for Patents and Technology Marketing and was promoted to Vice President of Cornell Research Foundation in 1993. Since 2002, he has been Acting Director of the Office of Patents and Technology Marketing and President of Cornell Research Foundation, Inc. Since a recent reorganization of Cornell's technology transfer operation, he has held the title of Acting Executive Director of the Cornell Center for Technology, Enterprise, & Commercialization (CCTEC). CCTEC is Cornell's new center which integrates intellectual property management, licensing and economic development.
Dr. Cahoon has nearly twenty years experience in various aspects of technology management, including R&D, product development, entrepreneurship, strategic alliances, intellectual property and licensing. He is an inventor and holds a U.S. patent on a bioprocess system. Dr. Cahoon completed his PhD in Natural Resource Policy and Law with a dissertation that focuses on the relation of intellectual property from wild biota to biological resource conservation law and policy.
Peter Chant
Peter Chant is President of The FReMCo Corporation. The FReMCo Corporation is a group of consultants operating in the area of strategic corporate growth with a focus on maximizing the value of technology and increasing bottom line performance/revenue in all areas of a business.
Peter has two Bachelor of Science degrees, one in Pure Sciences from the University of Durham and the second in Civil Engineering from the University of Newcastle.
Prior to starting The FReMCo Corporation in 1981, Peter worked for Shell International Chemical Company based in Delft and Amsterdam in The Netherlands. He worked in technical and market development in various areas of the polymers business including thermoplastics, foams and epoxy resins. Specifically, he was responsible for The Foam Reservoir Moulding Process that was licensed in North America by John DeLorean.
Peter is currently Chairman of the Board of CleanAir Canada Inc., a not-for-profit organization dedicated to the increased use of emission credit trading in Canada.
Kevin Chen
Dr. Kevin Chen currently serves as President of Shanghai South Gene Tech. Co. Ltd. a R&D arm of China National Human Genome Center, Shanghai, working on genotyping and therapeutic protein engineering. He is General Manager and co-founder of IgCon Therapeutic Company, a biotech company (JV of Genetastix, USA and China National Human Genome Center, Shanghai) focusing on therapeutic human antibody development for Asian health care market. Dr. Chen was appointed as the Director of R&D Center, Novo Nordisk China in 1997. During his near four years' experience in Novo Nordisk, Kevin had built and consolidated three research units in addition to two service centers that support global business and R&D operations of Novo Nordisk A/S. Kevin served as a member of board of Cooperate Research Affair, Novo Nordisk A/S, Denmark, and member of board directors of China Management (ChinaMan) Group, Novo Nordisk China.
Dr. Chen has developed an excellent track record on both industrial and academic research in the United States (1990-1997). Before joining Novo Nordisk, he was a principal investigator at Central Research & Development, DuPont Company, USA. Kevin also worked as a senior research fellow in the Bioprocess Engineering Development Center at the Massachusetts Institute of Technology (MIT), USA. During his postdoctoral study at the California Institute of Technology (Caltech), USA, Dr. Chen pioneered the concept and technology of directed molecular evolution for protein engineering in non-aqueous solvent.
Kevin Chen is originally from Shanghai, China. He received an award of CUSBEA (China and United States Biochemistry Exchange and Application) and went to U.S.A. for his Ph.D. study in 1985. He received a Ph.D. degree from University of Minnesota, Twin cities, USA.
Yiyou Chen
Dr. Chen is the Chief Scientific Officer and Co-founder of Starvax Inc., a biopharmaceutical company focusing on the development of novel immunotherapeutics for the prevention and treatment of infectious disease and cancer. He is responsible for overseeing research and development activities in the company. Prior to founding Starvax, Dr. Chen has served as the project leader for the immunotherapuetics project for chronic hepatitis B and HPV infection at Genencor International, a large diversified biotech company with over $ 380 million revenue annually. The project was later sold to Innogenics for $90 million. Dr. Chen obtained his BS in Biochemistry from Peking University, and his Ph.D. from University of Utah School of Medicine in Experimental Pathology. He has authored and co-authored many scientific papers and abstracts, and is the inventor and co-inventor and over 10 patents and patent applications.
Charlotte Clark
Ms. Clark has been a general partner of POSCO BioVentures since its inception in 2002. She has more than 17 years' experience in the Biotechnology industry, and has been a founder of four companies, including Cygnus, Inc. and Nereus Pharmaceuticals. She has served in senior management positions since 1985, in both finance and business development positions. Previously, Ms. Clark served as Vice President, Business Development at Myelos Corporation, a neuroscience company, where she was instrumental in selling the company to Savient Pharmaceuticals (formerly Bio-Technology General Corporation). Ms. Clark is a member of the Licensing Executives Society, and is also involved in the Biotechnology Industry Organization. She serves on the Board of Directors of Accera Pharmaceuticals, Inc. and is an observer on three other boards. Ms. Clark has a B.A. from the University of Virginia and an M.B.A. from the Anderson School at UCLA.
Gary Cleary
Dr. Gary W. Cleary is an internationally recognized scientist in the field of drug delivery systems and polymer technologies as well as co-founder, President, and Chief Technology Officer of Corium International, Inc. Corium (http://www.coriumtech.com) specializes in dermal, transdermal, mucosal and transmucosal drug delivery platforms and manufacturing systems. Corium uses a Total Process Approach to develop, and manufacture delivery systems for use in immediate, intermittent and controlled release drug products. Corium's specialty is in prescription drug products that require adhesion to biomembranes.
Dr. Cleary holds 25 issued US patents, many other patents pending related to transdermal, mucosal, polymer and other drug delivery technologies. In 1991, he received the Entrepreneur of the Year Award in Life Sciences for Northern California. He recently received the 2004 Biomaterials Entrepreneur Award of the New Jersey Center for Biomaterials.
Dr. Cleary earned a Pharm.D. degree from the University of California, San Francisco, an MBA in health sciences from the University of Miami, and a Ph.D. in pharmaceutics from Rutgers - The State University of New Jersey. During his career, he held research and management positions at the FDA, Alza Corporation, Key Pharmaceuticals, Genentech, and Cygnus, a company that developed the Ortho-Evra Patch and now produces self-monitoring devices for glucose measurements. Cleary founded Cygnus in 1985 and served as its President, Chairman, and Chief Technical Officer.
Cleary is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American Institute of Medical and Biomedical Engineering (AIMBE) and past president of the Controlled Release Society (CRS). Cleary's professional affiliations also include the New York Academy of Sciences (NYAS), American Association for the Advancement of Science (AAAS), and the professional societies Rho Chi and Sigma Xi.
Cleary is a member of Rutger's and Purdue University's Biomedical Engineering Advisory Board and the Pharmaceutical Advisory Board of the University of California, San Francisco and of the University of Pacific. Dr. Cleary is a member of the Commercialization Board of the Center for Military Biomaterials Research (CeMBR), a program of the New Jersey Center for Biomaterials (NJCBM). Cleary serves on the Board of Directors at Corium, Anterion, in Boston MA, and Community School of Music and Arts, in Mt. View CA.
Walter Copan
Dr. Walter G. Copan joined the National Renewable Energy Laboratory of the U.S. Department of Energy in the capacity of Principal Licensing Executive in the summer of 2003. His responsibilities include the licensing and commercialization of clean energy, energy efficiency and related technologies, enterprise development, and industry partnerships for business development.
Prior to joining NREL, Dr. Copan was Managing Director, Technology Transfer and Licensing for The Lubrizol Corporation, where he was responsible for Lubrizol's global external relationships for technology, and the corporation's technology transfer and licensing business. In this capacity, he led Corporate Intellectual Asset Management for financial and strategic business impact, and corporate venturing and new business incubation. He provided leadership in international commercial development of new technologies, as well as corporate technology strategy. He contributed to developing alliances as well as mergers and acquisitions options for Lubrizol, and in strategic planning.
Previous assignments in Dr. Copan's 28 year career with Lubrizol include a variety of leadership roles in research, product development, strategy, new ventures, business development and commercial management. He also headed Lubrizol Petroleum Chemicals Technology based in the UK, with responsibility for product development, program management and technical service for Lubrizol's business in Europe, the Middle East, Africa and the Former Soviet Union.
His undergraduate degrees from Case Western Reserve University are in chemistry and music. He chose chemistry and business over the option of a musical career (opera, vocal performance) and and received his Ph.D. in Physical Chemistry at Case Western Reserve University.
He has authored numerous professional publications and presentations, and serves on the board of directors for several organizations. Technical and professional society memberships include the American Chemical Society, Council for Chemical Research, Society of Automotive Engineers, the Association of University Technology Managers, and the Licensing Executives Society (LES). Within the LES USA & Canada he serves as chair of the LES E-104 Energy, Chemicals and Materials Committee, and as a Trustee of the LES, with responsibilities for Mentorship, and as past chair of the Industry-University Government Laboratories Transactions Committee (LES E-108). Dr. Copan also chairing the LES International (LESI) Chemicals, Energy and Environment Committee, is incoming co-chair of the LESI Industry-University and Government Laboratories Transactions Committee and serves as international delegate to LESI. He also serves as member of the National Advisory Council to the Federal Laboratory Consortium.
Molly O'Donovan Dix
Molly O'Donovan Dix is a Sr. Commercialization Manager at RTI International. She has been actively managing intellectual property for external clients, with a focus on licensing, for more than 12 years. Within RTI International's Center for Technology Applications she is a client and project manager for clients such as NASA, Whirlpool, Osram Sylvania, Georgia Tech, University of Miami, Ballistic Missile Defense Organization, Kimberly Clark, and the U.S. Department of Energy. She has collected, organized, and analyzed market intelligence for her clients for commercial opportunity analyses, marketing strategy development, and licensing. Her efforts in identifying and securing licensees have resulted in more than 30 licenses, and Ms. Dix has won four awards (three from NASA and one from the Federal Laboratory Consortium for Technology Transfer) for her exceptional performance in technology commercialization. In addition to these activities, Ms. Dix has worked with industry associations to investigate applicable technologies for industry-based problems. National associations and consortia included food processors, equipment manufacturers, energy associations, aerospace organizations, and others. Molly received a B.S. in Mechanical Engineering from the University of Rochester and a Master's of Intellectual Property, Commerce, and Technology from the Franklin Pierce Law Center.
Andrea Doering
Andrea Doering is University of Maryland Baltimore's Manager of
Technology Commercialization. Andrea's primary responsibilities include
the evaluation of technologies for marketability, the development and
implementation of a marketing plan for each technology and the
negotiation of business terms with potential licensees. Andrea joined
TEC-COM in June 1999 after 10 years as a scientific researcher and 2
years in corporate consulting. Andrea is a Licensed Patent Agent and
holds an MBA from University of Southern California, a PhD in Physiology
(Biophysics) from the University of Maryland, Baltimore and a BSE in
Biomedical Engineering from Duke University.
Richard Donaldson
Employed by Texas Instruments, Inc (TI) for thirty-one years, retiring in 2000 as Senior Vice President and General Patent Counsel. While General Patent Counsel he managed a department that included over 40 patent attorneys and agents. He developed licensing strategies for handheld calculators, personal computers and integrated circuits and had the direct responsibility for implementing those strategies, worldwide. Published figures for TI net royalty income (1989-1995) for licenses he personally negotiated exceed $4 billion. Since retiring from TI he has served as an expert damages witness in numerous patent lawsuits in the semiconductor, computer and telecommunications fields.
Dave Drab
Dave Drab is the Director of Information Content Security Services for Xerox Global Services which provides consulting services and solutions to corporations throughout North America.
The focus of the practice is to protect critical business information in document intensive business processes,SM where intellectual assets and trade secrets are vulnerable to theft or loss. This is accomplished in part by better structuring documents and document content to be more active, more intuitive, and less dependent on human decision-making.
The objective of these solutions and consulting services is to reduce embedded costs, improve productivity, and assure the confidentiality, integrity, and availability of the critical document content that makes the enterprise competitive in a global marketplace.
Drab is a 32 year veteran of law enforcement and joined the Xerox Corporation in 2002 upon his retirement from the Federal Bureau of Investigation after 27 years service. He had extensive experience in the organized crime investigation and specialized in foreign counterintelligence and economic espionage in the final years of his career. Drab received his Bachelor of Science in criminal justice from American University in Washington, D.C.
Arian Duijvestijin
Arian Duijvestijin is Senior Vice President, Philips Intellectual Property & Standards.
A native of the Netherlands, he graduated in technical physics from Delft Technical University and joined Philips in 1986. Arian has held various positions in development of optical drives before joining Philips Intellectual Property & Standards in 1993. In 1997 he qualified as European Patent Attorney. In 1998 he was appointed to Patent Portfolio Manager of the Philips patent portfolio that relates to the activities of Philips Semiconductors. In June 2004, Arian wasÊappointed Patent Licensing Director General.
Steven Ferguson
Steven M. Ferguson currently serves in the NIH Office Of Technology Transfer as the Director and senior licensing professional for a forty-member Division of Technology Development and Transfer, the patent & licensing group for NIH and FDA technologies. Prior to rejoining NIH in 1990, Mr. Ferguson served in marketing and management positions in such biomedical firms as Pharmacia Fine Chemicals and LKB Instruments subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital.
A registered Patent Agent, Mr. Ferguson holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor's Degree in Chemistry (Case Western Reserve University).
Mr. Ferguson is a project reviewer for the Maryland Industrial Partnerships (MIPS) Program and is the licensing instructor for both the USDA Graduate School and the NIH FAES courses on Technology Transfer. He is the co-author of Starting & Operating A Business in the District of Columbia and Starting & Operating A Business in West Virginia, both published by Oasis Press. Mr. Ferguson was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory and has published articles on licensing and technology transfer issues in such publications as Journal of Biolaw and Business, Journal of Pharmaceutical Development & Regulation and Drug Discovery Today.
He has received the NIH Director's Award and four NIH Merit Awards in recognition of his activities in the management and negotiation of technology licensing agreements from the National Institutes of Health.
Joseph Ferraro
Joseph Ferraro has been managing and trying complex lawsuits for more than 30 years, including more than 10 years devoted exclusively to IP disputes. He is the author of numerous articles on litigation and intellectual property subjects, including Objections Raised Over Technical Advisors, in Litigation, NewYork Law Journal, Oct. 15, 2002 at S5; 2001 Patent Law Decisions of the Federal Circuit, 51 Am. U. L. Rev. 639 (2002); 'Markman' Survey Shows Rise in Summary Judgments, in Intellectual Property, New York Law Journal, May 13, 2002 at S6. He has spoken frequently on intellectual property and licensing issues, including presentations to add-on seminars at the LES 2003 Annual Meeting and the LES Spring 2004 Meeting and to the LES San Francisco Chapter (Controlling the Risks of an Assertion Licensing Program, May 2004). He is a member of the New York and California bars. Since his retirement as a partner of Clifford Chance US LLP in August, 2004, he has been engaged in providing mediation services in intellectual property, licensing and other complex disputes.
James Foley
Dr. Foley is a Vice President in Bristol-Myers Squibb's corporate and business development group with primary responsibility for the Asia/Pacific area. Dr. Foley rejoined Bristol-Myers Squibb in his current position April 1, 2002 after spending 10 years at SmithKline Beecham and GlaxoSmithKline in a similar role.
Dr. Foley's career in the pharmaceutical industry began in 1977 at the Squibb Institute of Medical Research (E. R. Squibb and Sons). After 12 years in R&D, he joined the Department of Licensing and Business Analysis at Squibb and relocated to Tokyo, Japan in 1989 to manage the company's licensing activities related to Japanese pharmaceutical companies. Dr. Foley remained with Bristol-Myers Squibb after the merger and joined SmithKline Beecham in 1991 where he remained based in Tokyo until 1995.
Dr. Foley has served on the Boards of Directors of St. Peter's School (Philadelphia), Sosei & Company, Inc. (Tokyo), the Japan-America Society of Greater Philadelphia and the New York Pharma Forum. He also serves on an Advisory Committee for the Haub School of Business (St. Joseph's University, Philadelphia) and chairs the Japan- Philadelphia Health Sciences Dialogue, an annual meeting held in Philadelphia addressing healthcare issues/solutions in the US and Japan.
Born November 5, 1944, Dr. Foley holds a Ph.D. in Physiology and Pharmacology from Thomas Jefferson University, where he received a graduate fellowship from the Charlotte Drake Cardeza Foundation for Hematologic Research in the laboratory of Dr. Allan J. Erslev (Director and Cardeza Research Professor of Medicine), and a BA in Biology and Chemistry from Rutgers University. He was a NIH Post Doctoral Fellow from 1975 to 1997 in the Laboratory of Hematopharmacology under Dr. James W. Fisher, Professor and Chairman, Department of Pharmacology, Tulane University School of Medicine in New Orleans.
Ed Gates
Ed Gates is a Shareholder and Managing Partner of the IP law firm of Wolf, Greenfield & Sacks, P.C. He has particular expertise in assisting early-stage companies in developing effective intellectual property strategies and is co-founder and director of a private, start-up biotechnology company. Ed works closely with nonprofit research institutions and has developed innovative technology transfer programs for certain of his nonprofit clients. Ed speaks frequently on intellectual property law issues at legal and industry conferences such as the MIT Enterprise Forum Technology Transfer Conferences, the American Intellectual Property Law Association, the Licensing Executives Society and the Association of University Technology Managers.
Mark Grant
Mark Grant is a practicing attorney specializing in litigation strategy development and management, technology licensing, intellectual property counseling, and infringement avoidance programs, and has over 30 years experience in semiconductor technology, electronics, computers, software, and related fields. He has held various legal positions such as Vice President, General Counsel at Mosel Vitelic Inc., and Director of Intellectual Property at National Semiconductor Corporation. While at National he supervised thirteen patent professionals, and implemented their licensing program, generating hundreds of millions of dollars in licensing revenue. While at Mosel he successfully defended the company against numerous patent litigations including multiple federal district court cases, International Trade Commission investigations, as well as anti-dumping cases. He has also held engineering and management positions such as microprocessor specialist at Texas Instruments, project manager at Chrysler Corporation, and design engineer at General Motors.
Mr. Grant received a BS in Engineering (Electrical) with honors from Oakland University, an MS in Engineering from the University of Michigan, and a Juris Doctor, cum laude, from Santa Clara University School of Law. He is admitted to practice in California, the District of Columbia, the U.S. Court of Appeals for the Federal Circuit, the U.S. Patent and Trademark Office, and before the U.S. Tax Court.
Professional affiliations include: IEEE-CS Board of Governors (2000-2005); American Intellectual Property Law Association (Practice in Japan Committee); American Bar Association, Licensing Executive Society; Phi Delta Phi International Legal Fraternity (Life Member); Intellectual Property Section, State Bar of California; Santa Clara University School of Law Ð High Tech Advisory Board (1997-2001); Department of Commerce Ð Auto Parts Advisory Group (1986-1994); and Department of Commerce Ð Japanese negotiations task force, MOSS conferences (1986).
Robert Gould
Dr. Gould is currently Vice President, Licensing and External Research, Boston, Merck Research Labs. His responsibilities include identifying early stage opportunities for collaboration or licensing with both academic and biotechnology institutions.
Dr. Gould obtained his Ph.D. in biochemistry in 1981 at The University of Iowa under the guidance of Dr. A. A. Spector, after completing his undergraduate degree in chemistry at Spring Arbor College, Michigan. He then moved to the Departments of Pharmacology and Experimental Therapeutics, and Neuroscience at Johns Hopkins University, Maryland for post-doctoral studies with Dr. S. Snyder. In 1984 he joined Merck Sharp and Dohme Research Labs as a Senior Research Pharmacologist in the Pharmacology department. He has remained with Merck Research Labs for 20 years. During this time, he was responsible for identifying compounds which block glycoprotein IIb/IIIa on platelets and thus might be useful antithrombotic agents. This work culminated in the identification of AggrastatÔ. Prior to his current position he was Vice President, Basic Research, in West Point, Pennsylvania where he oversaw strategic direction and drug discovery activities for several therapeutic areas, as well as MRL's centralized high throughput screening and imaging facilities.
Dr. Gould is a member of the American Society for Biochemistry and Molecular Biology, the American Society of Pharmacology and Experimental Therapeutics, the American Heart Association and the American Association for the Advancement of Science. He has published over 80 peer-reviewed publications and has received numerous awards including the American Oil Chemists' Honored Student Award, the Clarence P. Berg Award for the outstanding graduate student in biochemistry at the University of Iowa, the Johns Hopkins University School of Medicine Award for Postdoctoral Investigation, the Alumni Career Achievement Award from Spring Arbor College, Fellow of the American Heart Association, and induction into The Johns Hopkins University Society of Scholars.
Frank Grassler
Frank Grassler is Vice President of US Intellectual Property, Biotechnology & Litigation for GlaxoSmithKline at their Research Triangle Park, North Carolina facility. He is a graduate of the University of Colorado Schools of Law and of Pharmacy. He has practiced for twentyone years in the pharmaceutical industry in the fields of organic medicinal chemistry, vaccines, targets, screening technologies, bioinformatics, genetics and pharmacogenetics. He was a civil litigator and then served in the patent departments of G.D. Searle and Company, now part of the Pfizer group, and Merck and Co., Inc., before joining GlaxoSmith Kline.
R. Mark Halligan
R. Mark Halligan, Esq. is a principal in the Chicago intellectual property law firm of Welsh & Katz, Ltd. and he also serves on the Adjunct Faculty at John Marshall Law School in Chicago where he teaches Advanced Trade Secrets Law and Trade Secrets Litigation. A prolific lecturer and writer on the law of trade secrets, Mr. Halligan has sponsored the world-renowned TRADE SECRETS HOME PAGE on the Internet since 1994 and he is recognized nationally as an expert in trade secrets law and the Economic Espionage Act of 1996. Mr. Halligan is a first-chair litigator and his practice includes all aspects of intellectual property law, Internet law, and related licensing and antitrust matters. In recent years, Mr. Halligan has been at the forefront of several emerging legal practice areas including intellectual asset management (IAM), competitive intelligence and counterintelligence programs, digital evidence discovery and the economic valuation of intangible assets.
Paul Hansen
Paul Hansen is a Principal with Towers Perrin's Health and Welfare practice in New York serving as a client relationship manager for Pfizer Inc. He has more than 25 years experience in conducting management consulting engagements on a global basis. He has completed numerous strategy development, organization effectiveness and HR process reengineering projects. Some of his current clients include, Pfizer Inc, Boehringer Ingelheim, Merck & Company and Serono.
Mr. Hansen has conducted many assignments in the pharmaceutical industry but also in financial services, engineering/construction, process and discrete manufacturing, consumer packaged goods, not-for-profit organizations and specialized business sectors. His consulting experience spans a wide range of functions, including human resources, sales and marketing, finance, product development, and information technology.
Before he joined Towers Perrin, Mr. Hansen was a principal with Hayes-Hill, Inc., a strategy and HR organizational consulting company that merged with Towers Perrin in 1986. Mr. Hansen has an M.B.A. in finance from the Stern School of New York University. He is a member of the Board of Directors of the Strategic Planning Institute, New York Chapter. He has published articles in a number of business journals and has lectured on a range of business topics at leading business schools and professional organizations.
Neil Hargreaves
Neil Hargreaves is a Senior Manger with PricewaterhouseCoopers LLP in the United Kingdom and specialises in assisting clients maximise the value of their intellectual property through the active management and enforcement of license agreements. He has carried out royalty examinations for clients throughout the world and in a variety of industries and helped them recover millions of dollars of unpaid royalties. He is a regular speaker on the subject of management and valuation of intellectual property.
James Hattersley
Sr. Director Business Development since January 2000. Prior to joining Eurand, Mr. Hattersley was a director at Anesta where he was responsible for partnering Actiq¨ with licensees in the Pacific Rim region. Between 1995 and 1998, on behalf of the Swiss based Jago / Permatec group of companies, he held positions charged with instituting program management and business development strategies in the United States. From 1990 through 1995 Mr. Hattersley was a scientist at Abbott Laboratories under the charter of PPD where primary objectives were R&D formulations development of proprietary compounds. After completing his undergraduate and graduate education in 1986, his technical experience at Alza allowed for development of a foundation in the drug delivery sector of the pharma industry. Mr. Hattersley received a B.A. degree in neurobiology in 1985 and an M.S. degree in Biochemistry in 1986 both from the University of California, Santa Cruz.
Craig Heim
Craig Heim is a Vice President, Chemical M&A, in the Milwaukee, Wisconsin office of Grace Matthews, Inc., an investment banking firm that provides financial advice to middle-market businesses and large, multi-national corporations. Craig's practice involves providing guidance to corporate clients on mergers, acquisitions and leveraged finance/management buyouts in Grace Matthews' chemical sector.
Prior to joining Grace Matthews, Craig spent five years in operations management, process engineering, and product development with International Paper. Craig holds both an MBA and a BS in Chemical Engineering from the University of Wisconsin - Madison. At Madison, Craig was a Weinert Fellow in the graduate entrepreneurship program.
Craig is currently the National Membership Chair for the Commercial Development and Marketing Association. He is also on the board of directors of the Milwaukee Chapter of Ducks Unlimited and the Southeast Wisconsin Chapter of Trout Unlimited.
Anthony Higgs
Anthony Higgs is the Intellectual Property Director for the Sensors & Electronics Division of QinetiQ. This company is based in the UK and is the largest science and technology organisation in Europe, holding over 4000 patents. He leads a team that has the responsibility for the generation, management and exploitation of intellectual property within the Division, and for enforcing QinetiQ's IP rights. An important part of managing the licences with licensees is the need to undertake royalty audits. He has undertaken a number of royalty audit programmes, which have proved highly successful. Significant levels of under-reporting have often been identified and settlements have already netted millions of dollars.
Linda C. Hogan
Linda C. Hogan is Vice President, Business Development of Clearview Projects in Princeton, New Jersey. Clearview Projects is an innovative company providing biopharmaceutical companies with transaction-oriented deal planning, preparation, and execution. Linda has nearly 20 years of experience working in major pharmaceutical companies, including her recent responsibilities as Vice President, US Group Head, Global Business Development at Aventis. She was responsible for identifying, evaluating, and negotiating licensing opportunities for Aventis as well as managing the US Office of Global Business Development. She began her career in the pharmaceutical industry as a senior scientist in the medical affairs department at Marion Laboratories, Inc. Through a series of mergers, she held successive positions in strategic planning and licensing at Marion Merrell Dow Inc., Hoechst Marion Roussel and Aventis. Prior to joining Marion, Linda was an Assistant Professor and Director, Drug Information Service, at the University of Kansas School of Pharmacy and Hospital Medical Center. She holds both a BS and MS from University of Kansas School of Pharmacy and completed her residency of Hospital Pharmacy, University of Kansas Medical Center and Hospital. She received her MBA from Rockhurst College in Kansas City, Missouri.
Mark Holmes
Mark Holmes is the President and founder of PatentBridge LLC. (www.patentbridge.com)
PatentBridge is the bridge between patents and revenue. We offer a turn-key service for patent owners seeking to license or sell their select patents on a success-fee basis. We commercialize the portfolio. We take all steps necessary to turn the patents into revenue-generating licenses or capital-producing divestitures.
Our turn-key approach is especially attractive to corporations which do not have the ability, resources or inclination to commercialize their patent portfolio on their own.
PatentBridge offers the unique, but essential, combination of:
- experience in identifying licensees
- experience in identifying infringers
- a solid background in science and engineering
- a sound knowledge of patents
- the proven ability and expertise in negotiating license agreements.
The founder of PatentBridge has advised some of the world's leading technology companies on licensing matters, including Visa, Sony, Applied Materials, Fairchild Semiconductor, Yamanouchi Pharma, VISX, Berkeley National Lab (UC Berkeley) and Rigel Pharmaceuticals.
He is also an AV-rated patent attorney who speaks nationally on licensing and is the author of the book PATENT LICENSING: NEGOTIATION, STRATEGY AND FORMS (www.pli.edu). He earned his engineering degree from Brown University.
Jeet Hothi
Since receiving a graduate degree in engineering from Carleton University, Canada, Mr. Hothi has been working in the field of telecommunications in various capacities.
As a senior engineer in the Space Branch of the Department of Communications, he worked in the area of satellite communications.
He then joined the Technology Assessment Branch, where he was responsible for assessing newly emerging technologies such as fibre optics, data communications networks, wireless and other telecommunications technologies.
Since 1990, he is working at CRC, where he is currently the Manager of Technology Transfer and is responsible for IP protection and commercialisation through technology transfer and collaborative research with industry. He has also worked extensively with the private companies through the Industrial Research Assistance Program.
Jeet was responsible for leading and winning a patent interference legal case against two multinational companies - Corning and Lucent. This was the first time for the Canadian Govt to ever fight and then win such a case. He has won numerous awards including three awards for his work in tech transfer - President's award, Queen's Jubilee award and Federal Partners in Technology Transfer award.
Wendy Johnson
Wendy Johnson has broad experience in regulatory affairs, licensing, negotiation, establishment of international strategic alliances, acquisitions and various business relationships. Experienced with device, diagnostic and drug discovery and development, and regulatory affairs. Is known for intelligence, strong leadership capabilities, negotiation, managerial and communication skills. She joined Salmedix in April 2001 as Senior Vice President, Corporate Development. From July 1998 until July 2000 she served as Vice President, Business Development. From July 1994 until joining Women First, Ms. Johnson was Vice President, Corporate Development & Operations at Prizm Pharmaceuticals, currently Selective Genetics Incorporated. From July 1990 to June 1994, Ms. Johnson was Vice President, Business Development and Regulatory Affairs with Cytel Corporation. From June 1988 to June 1990, Ms. Johnson was with Symbiotics Corporation as Manager, Business Development. She worked for Murex Corporation, Cambridge U.K. as International Affairs Administrator from 1986 to 1988. From 1976 to 1986, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the Food and Drug Administration. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.
Nigel Jones
Nigel Jones is the head of both the intellectual property and healthcare groups of international law firm Linklaters, based in its London office. He advises many of the world's leading companies on intellectual property, anti-trust, regulatory and commercial matters - in both the contentious and non-contentious areas. This includes advising on the European anti-trust implications of technology transfer agreements and, through his LES role and in other ways, influencing the development of legislation in this area. He is a graduate (in biochemistry) of Oxford University, an active member of LES and a number of other professional associations, and a member of the editorial board of the Bio-Science Law Review.
Gayle Kirkpatrick
Gayle Kirkpatrick is a Senior Director of Scientific Assessment and Licensing in the Global Pharmaceutical Licensing and New Business Development group at Abbott Laboratories. Gayle leads a team of Senior Managers in the establishment of licensing priorities and in the identification and evaluation of new strategic partnerships and licensing opportunities that may augment Abbott's global pharmaceutical business and research efforts.
Over her 15 years of tenure at Abbott, Gayle has gained experience in several areas including pharmaceutical R&D, program management and business development. In addition to her pharmaceutical industry experience, Gayle was a Licensing Associate for the Wisconsin Alumni Research Foundation (WARF), the technology licensing office for the UW-Madison, where she was responsible for licensing interactions with pharmaceutical and biotechnology companies. While at WARF, Gayle assisted in the establishment of WiCell, the stem cell research institute in Madison, and served as Vice President and General Manager.
Gayle holds a degree in Pharmaceutical Science from the University of Wisconsin-Madison, a MBA from the J.L. Kellogg Graduate School of Management, Northwestern University and she is a registered pharmacist.
N. Peter Kostopulos
N. Peter Kostopulos, is a partner in the Life Sciences group of Womble Carlyle, Sandridge & Rice PLLC, a major East Coast-based US law firm, and Leader of its BioAlliance Practice. Mr. Kostopulos represents private, venture backed companies in corporate partnering activities involving pharmaceutical, biotechnology, and medical device products and technologies. He has drafted and negotiated over 75 domestic and international collaborations and intellectual property transactions, many of which involved providing direct support to steering committees and alliance management. He is also an expert in resolving business disputes relating to intellectual property rights, licensing issues, and alliance governance. His litigation experience, while in private practice and during his service with the United States Department of Justice, during which time he conducted over 70 jury trials, arbitrations, and mediations, provides clients with valuable assistance in avoiding and resolving costly litigation. He is knowledgeable about antitrust and competition law, gained from his years of counseling clients on licensing activities and during his early career service with the Federal Trade Commission, one of the principal antitrust policy and enforcement departments of the United States government. Peter has been a proud member of the LES for 10 years, and serves as co-Chair of LES's Strategic Alliance Committee. He is also a member of the American Bar Association's Business Law and Intellectual Property Committees. He received his B.A. in 1974 from Georgetown University and his J.D. in 1978 from the Georgetown University Law Center and is a member of the bars in Washington, DC, Florida, Virginia, and Maryland. Mr. Kostopulos has lived outside the United States and, besides English, speaks French and limited Greek.
Mark Lauroesch
Mark Lauroesch is Division Vice President, Director of the Intellectual Property Department, and Assistant Secretary to Corning Incorporated. In this capacity, he oversees all intellectual property matters for the company and its majority-owned subsidiaries. Prior to joining Corning, he practiced intellectual property law in Washington, D.C. as an associate of the law firm Finnegan, Henderson, Farabow, Dunner & Garrett. Mr. Lauroesch joined the Finnegan law firm after a judicial clerkship with the Honorable Paul R. Michel on the U.S. Court of Appeals for the Federal Circuit. Before attending law school, Mr. Lauroesch was a Senior Research Engineer with Northrop Corporation. He graduated from St. Lawrence University with a B.S. with Highest Honors in Physics, obtained a M.S.M.E. from the University of Massachusetts, and received his J.D. from The National Law Center at George Washington University. He is a member of the New York, Massachusetts, and District of Columbia Bars, and is registered to practice before the U.S. Patent and Trademark Office.
David Maher
David W. Maher, a graduate of Harvard College, '55 and Harvard Law School '59, is a registered patent attorney, and the author of many articles on the Internet, copyright and trademarks. He was a member of the International Ad Hoc Committee (IAHC) and chair of the Policy Oversight Committee (POC). He was one of the drafters of the policy document that became the ICANN Uniform Dispute Resolution Policy (UDRP). He served as Vice President - Public Policy of the Internet Society, and is now Chairman of the Board of the Public Interest Registry, a nonprofit corporation responsible for management of the registry of the .ORG top level domain. He is a member of the American Law Institute.
Panos Malamis
Panos started his career in Jewelry. He held several posts in Commercial positions (retail sales, wholesale, marketing) and then entered the field of jewelry design and manufacturing. While in design he was involved in prototype design and in the translation of market trends and demands into product lines.
After obtaining and MBA from the Rotterdam School of Management, he joined the marketing department of L'Oreal where he was responsible for the management of brands (Hair & Body Skin care). Following L'Oreal, Panos joined The Coca Cola Company again in the marketing department responsible for several soft drink brands.
In 1999 Panos joined the firm Malamis & Malamis that was established A.D. Malamis in 1951. Malamis & Malamis is an IP boutique providing a service to clients that covers the whole IP value chain, from creation to commercialization. Panos since establishing the licensing side of the firm is involved in IP matters that have a commercial outlook, including IP licensing, IP commercialization, market research and analysis, negotiations, damages estimation. Currently a large part of his practice is in matters related to cyberspace licensing and commercialization.
Panos is involved in several international IP organizations, is Chairing the IP Marketing Team of MARQUES - The Association of European Trademark Owners, is a Vice - Chair of the LESI Communications Committee and is a member of the IT and E-commerce Committee of LES International.
David Marston
Mr. David Marston is a partner in the Advisory practice at PricewaterhouseCoopers in San Francisco. He has been with PwC for 15 years, and is the national leader of the Licensing Management practice. He serves companies in various industries, on a variety of intellectual property issues, including license management and compliance.
Michael Martin
Michael J. Martin, Executive Vice President, Virginia Tech Intellectual Properties, Inc. has over 30 years of technology development experience, 16 years in industry and over 18 years at Michigan State University and Virginia Tech Intellectual Properties, Inc.. He has been elected as a Trustee of the Licensing Executive Society (LES), and has been responsible for the development and transfer of technology; formulation and execution of new business plans; and growth of economic development strategies. Mike has a B. Ch. E, and an M. B. A.
Christine Mayer
Christine Mayer is a multi-disciplined executive, with over 20 years of broad business experience, of which 16 years were spent in the pharmaceutical industry across several disciplines and therapeutic areas.
Christine currently holds the position of V.P./U.S. Group Head in Global Business Development at Aventis. She is responsible for managing a team of executives who suppot both U.S. and global efforts in all aspects of Business Development including licensing opportunities, divestitures, marketing alliances and other partnerships.
Before joining Aventis, Christine worked for Johnson & Johnson for 13 years in the pharmaceutical sector. She has held many positions in various disciplines including Business Development, Marketing, Sales and Finance.
Christine holds an M.B.A. in Finance from Rutgers University and a B.A. from Glassboro State College.
Rob McInnes
Rob McInnes has over 15 years experience in the management, commercialisation and enforcement of intellectual property rights. Rob assists clients with the negotiation and drafting of collaborative R&D, licensing, distribution and joint venture agreements and with the establishment and financing of new technology ventures. His other areas of practice include marketing regulation, antitrust, unfair competition, product regulation and product liability.
Rob joined Spruson&Ferguson in 2003, having previously managed the successful establishment of the associated law firm of another patent attorney firm, and having been the in-house Manager of Intellectual Property and Technology Transfer with the James Hardie Group.
Rob is Senior Vice-President of the Licensing Executives Society of Australia & New Zealand and Vice-Chair of the Licensing Executives Society's International Working Groups on industry/university/government technology transfer, and health care licensing. He is a Chartered Chemist, and was a member of the Intellectual Property Working Group for the National Innovation Summit. Recently Rob was appointed to the Intellectual Property Committee of the Australian Institute for Commercialisation.
Rob is also an experienced professional trainer in the management and commercialisation of intellectual property rights.
Jim McLoughlin
Jim McLoughlin is a Director of Strategic Alliances at Pfizer. Jim is based at Pfizer's Headquarters in New York, working with Pfizer Licensing and Development on projects involving advanced licensing candidates where research collaboration is also under consideration within the relationship. Jim is also based in Pfizer's R&D Headquarters in New London, Connecticut.
Jim joined Pfizer Strategic Alliances in 1999. Prior to joining Pfizer, he held various scientific, business-development and licensing positions with Monsanto in St. Louis, Missouri. In his last five years at Monsanto, he was a member of the Genomics Business Team and previously a member of the Technology Alliances Team within Monsanto's M&A Group. Prior to joining Monsanto, Jim was a chemist with Chevron in Richmond, California.
Jim has a Ph.D. in organic chemistry from the University of California, Riverside and an MBA from the Olin School of Business at Washington University in St. Louis.
Kevin McMahon
Mr. McMahon is currently the manager of Licensing and Intellectual Property Management in the Corporate Business Development and Partnerships center at Sandia National Laboratories. He is responsible for managing the department that develops, matures, negotiates, closes, and nurtures commercial business licensing agreements. He networks with national industrial scientists, engineers, corporate executives, and legal counsel while managing Sandia's intellectual property, to ensure that commercial licensing agreements align with the missions or purpose of Sandia National Laboratories.
Mr. McMahon holds a Bachelors degree in Chemistry and Mathematics from the University of New Mexico. He also has a Masters in Business Administration with a concentration in Management Information Systems from the University of New Mexico. He is an adjunct professor at Webster University, Albuquerque Campus, where he teaches Statistical Analysis and a number of information systems courses in the MBA program. He has over 25 years of experience in both the public and private sectors.
Thomas Mercolino
Tom is the head of the group at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. that is responsible for a broad spectrum of licensing and agreement matters with universities, biotechs, and large companies, all with particular focus on Drug Discovery. His group provides service (>1200 agreements/year) to a varied client base, including chemists, biologists, physicians and marketing professionals. In his 6 years at J&JPRD, Tom also has obtained rights to a variety of new uses for marketed products, negotiated significant R&D tools agreements, and has supported diligence for compound licensing and strategic collaborations. He also implemented an efficient new web-based tool for agreements requests and tracking, which reduced agreement draft generation cycle time by more than 2/3 while reducing error rates.
Prior to Joining J&JPRD, Tom had a successful career of almost 20 years in diagnostics product development, first with Becton-Dickinson & Co. divisions, where he held technical and scientific positions of increasing responsibility. Later Tom joined J&J's Ortho-Clinical Diagnostics where he was the head of R&D for its Blood Bank and Immunocytmetry Systems businesses.
Tom has a PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill and a BS in Chemistry from Fairfield University. He is also a registered patent agent and the inventor of a number of issued patents.
Arlene Morris
Arlene M. Morris joins the Company as President and Chief Executive Officer, bringing significant expertise in the development of strategic partnerships, marketing and operations to Affymax. Ms. Morris has over 25 years of management experience from Johnson & Johnson, Scios Inc., Coulter Pharmaceutical, Inc., Corixa Corporation and most recently Clearview Projects.
Ms. Morris joins Affymax from Clearview Projects, where she was the President and CEO. Clearview Projects is an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Prior to that, she was the Senior Vice President, Business Development at Corixa, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases. She was appointed to this position in 2000 when Corixa acquired Coulter Pharmaceutical, Inc., where she had served as Senior Vice President of Business Development since 1996. While at Corixa/Coulter, she completed numerous transactions including the $1.0 billion merger between the companies and a contractual joint venture with GlaxoSmithKline (GSK) for Bexxar(r) valued in excess of $200 million. Previously, Ms. Morris was the Vice President of Business Development at Scios Inc. where she completed several high profile transactions including one of the first biotech profit sharing deals for a late-stage product.
From 1977 through 1993, Ms. Morris held various management and executive positions at Johnson & Johnson in sales, marketing and business development, holding the position of Vice President of Business Development for McNeil Pharmaceutical from 1988 to 1993. She received her BA degree in Biology and Chemistry from Carlow College, and studied marketing at Western New England College. She is a member of the Board of Directors of the Licensing Executives Society.
Kevin Nash
Mr. Nash has served as vice president, general counsel at Dharmacon since November 2002. Prior to joining Dharmacon, Mr. Nash served as executive director of legal affairs from 1999 through 2002 at Orchid BioSciences, Inc., a publicly traded biotechnology company. At Orchid, he oversaw all legal affairs for the company during its growth from 55 to 600 employees and its expansion into Canada and Europe. Previously, Mr. Nash was patent and licensing counsel from 1994 through 1998 at Integra Life Sciences Corporation, a publicly traded biotechnology company, where he oversaw all intellectual property affairs and contract negotiations for the company. Mr. Nash received his law degree in 1994 from Golden Gate University School of Law. Prior to law school, Mr. Nash received his B.A. in genetics and molecular biology from the University of California, Berkeley and received formal scientific training at the Salk Institute and Protein Design Labs. Mr. Nash is a registered patent attorney with the United States Patent Office.
Dale New
Graduated with Honors from the University Scholars Program of The Pennsylvania State University with a B. A. in Advertising, 1987. Senior Vice President of DePersico Creative Group, a Brand Image Packaging and Communication firm, one of the largest creative resources of its kind in the Philadelphia area. For the past 15 years, Mr. New has been advising and partnering some of the most aggressive and innovative marketers in the United States on issues of; Corporate & Brand Identity and Creation, Brand Launches, Brand Restages, Line Extensions, Identifying New Opportunities and the Packaging, Trade and Consumer Support and Promotions to make these a success. Some of the clients that he has served include; Campbell's Soup Company, Mrs. Smith's, Panasonic, Tastykake, Arm & Hammer, Primavera Software Systems, Lutron, and various Unilever brands. Mr. New regularly teaches seminars for undergraduate, graduate and international executive programs in Food Packaging and Branding for the St. Joseph's University Center for Food Marketing.
Mark Nuell
Dr. Mark Nuell is a registered patent attorney and partner at BSKB. Dr. Nuell has been working in the field of intellectual property since 1991. Dr. Nuell became a registered patent agent in 1993 and became a member of the Virginia bar in 1997.
In the course of his career as an intellectual property attorney, Dr. Nuell has assisted clients, including start-up and small companies, in the planning of their intellectual property strategy and in the obtaining of patent rights in their inventions. Dr. Nuell has obtained claims for clients having interests in many fields of genetic engineering, including cloned nucleic acids, vectors, vaccines, gene therapy, cell lines, recombinant proteins, antibodies, and various genetic engineering methods. Dr. Nuell has also done patent work in the fields of materials science, diagnostic and therapeutic compositions and methods, separation methods, analytic methods and the like.
Dr. Nuell has also performed services in the field of prosecution of interferences on behalf of clients. To date, he has participated in the prosecution or settlement of four interferences. Dr. Nuell also does a variety of opinion work, principally patentability, validity and infringement analyses.
Arthur Nutter
Arthur M. Nutter, BSME, MBA. Founded TAEUS International Corporation in 1992 as the first engineering company dedicated exclusively to intellectual property enforcement. His 34-year career in engineering and executive management with large multinational firms and small high tech startups enabled him to see how critical intellectual property management issues are to the success or failure of companies. Art has two patents pending on intellectual property management tools and processes. Art's ability to listen and solve problems helps translate customer requirements into solutions. TAEUS now assists corporations worldwide with intellectual property licensing, litigation, and management.
Douglas Olson
Douglas Olson focuses his practice on intellectual property law; including litigation to enforce intellectual property rights, patent procurement, and transactional work including licensing and due diligence. He was voted by his peers as one of "The Best Lawyers in America." He obtained a B.S. and M.S. in Chemical Engineering at the University of Wisconsin. His law degree was obtained from George Washington University. Mr. Olson's experience includes the position of Patent Examiner in the United States Patent Office and Law Clerk on the Court of Customs and Patent Appeals. He is involved in firm governance as a member of the Paul, Hastings, Janofsky & Walker LLP Policy Committee.
Mr. Olson has been lead counsel in over 60 intellectual property lawsuits. Over 30 of those cases were tried to a verdict. Many of those trial were jury trials in which he delivered opening statements and closing arguments. Mr. Olson also has an active appellate practice in both the Federal Circuit Court of Appeals and other regional Courts of Appeal.
Mr. Olson has published a number of articles relating to intellectual property law and is the author of the chapter on Trade Secret Evidence in the California Continuing Education of the Bar book, Proof in Competitive Business Litigation. He has also been a frequent lecturer regarding various topics in intellectual property law, including a speech to the Patent Examiners of the United States Patent Office regarding Examiner depositions. He has made presentations to the combined Orange County and San Diego Intellectual Property Law Associations regarding Willful Infringement and the Doctrine of Equivalents. Mr. Olson was voted by his peers as one of the "The Best Lawyers In America" (www.bestlawyers.com). He is also the only San Diego patent lawyer named in "Who's Who Legal."
Dwight Olson
Dwight C. Olson is vice president business development and was founder of Data Securities International (DSI) now a subsidiary of Iron Mountain Inc., America's largest records management company. Mr. Olson has over 39 years of experience in the computer industry. He began his career in the research and development of supercomputers, parallel processing systems and related system architectures in the 1960's.
Mr. Olson is an associate member of the American Bar Association's Electronic Commerce Law and Information Technology Division of the Section of Science & Technology, working in the area of global digital signatures. He is currently Regional Vice President, US for the Licensing Executives Society (LES) USA and Canada and has served as numerous computer and Internet committee chairman.
Mr. Olson often speaks on the topic of using technology escrow as a business tool and is currently sought after as a speaker on trusted third parties, security and authentication issues in the emerging electronic commerce applications on the Internet.
Mr. Olson received a bachelor's degree in mathematics in 1965 and a teaching certificate in 1966 from Augsburg College in Minneapolis, Minn. He attended post-graduate computer science courses at the University of Minnesota. Professional organizations with which he is or has been a member include: Association of Computing Machinery, Open User Recommended Solutions Task Force, American Bar Association (Information Security Committee), Licensing Executives Society, and the Information Technology Association of America.
Tim Oyer
Tim Oyer is a Shareholder in the intellectual property law firm of Wolf, Greenfield & Sacks, P.C. His practice involves worldwide patent prosecution, re-issues, opinions, agreements, foreign oppositions, trademarks, trade secrets, IP due diligence and related transactions and counseling in the areas of organic and inorganic chemistry, biotechnology, nanotechnology, pharmaceuticals, drug delivery compositions and vehicles, medical devices and diagnostics, optics, electrochemical devices, and polymer chemistry and processing. Tim serves clients in academia and industry, with an emphasis on helping high tech companies build domestic and international intellectual property portfolios, giving them the IP tools necessary to dominate their segment of the market and/or raise capital through private funding or public offering.
Alan Paau
Dr. Alan Paau is currently Assistant Vice Chancellor of Technology Transfer & Intellectual Property Services at the University of California San Diego. His office establishes relationships with the industrial and investment sectors and manages all inventions, patents, technologies, tangible research materials, most copyrighted materials and associated trademarks for the university. From 1994 to 97, he was Executive Director of the Iowa State University Research Foundation, Inc. and the Office of Intellectual Property & Technology Transfer at Iowa State University (Ames, IA). Previously, he was Associate Director of the Biotechnology Center at the Ohio State University (Columbus, OH) with responsibilities in research administration, technology development & transfer, and industry liaison. Dr. Paau held faculty appointments while at Iowa State University in the departments of Preventive Medicine, Immunology & Microbiology, and Genetics & Zoology, and at the Ohio State University in the departments of Microbiology, and Plant Pathology. Prior to Ohio State, Dr. Paau held various research and management positions in the Cetus Corporation and in the W.R. Grace & Co. organizations for 12 years. His research resulted in two commercial products.
Dr. Paau holds a Ph.D. degree in Biological Sciences, a Master of Business Administration degree and has formally enrolled in law school. He is a member of the Licensing Executive Society, Association of University Technology Managers, American Society for Microbiology, and the American Association for the Advancement of Science. Dr. Paau held 8 US patents and has thirty peer-reviewed technical articles and six invited reviews/chapters published in professional journals/books. As a director of intellectual property and a licensing executive, he supervised the execution of over 700 licenses and option agreements and the formation of over 60 startup companies using university innovations.
In 2002, Dr. Paau was recognized by the T-Sector Magazine in its "Power List 2002" as one of the "people whose efforts go beyond their own positions to influence the entire local tech and life sciences industry". In 2004, Dr. Paau was recognized by the San Diego Union-Tribute as one of the "People to Watch" in the San Diego business community.
Mark Palethorpe
Mark Palethorpe is a Divisional Finance Director for QinetiQ based in the United Kingdom. QinetiQ is Europe's largest science and technology organisation. The division in QinetiQ he represents employs 1,500 people and holds the majority of the Group's intellectual property portfolio. He is a fellow of the Institute of Chartered Accountants in England & Wales having qualified with Deloitte and Touche. He has held senior finance positions with Diageo, United Cinemas International (a Joint Venture with Paramount Pictures and Universal Studios) and EMAP Plc.
John Palfrey
John Palfrey is Executive Director of the Berkman Center at Harvard University. He is also a Lecturer on Law at Harvard Law School, and teaches courses on Internet law subjects. His research interests include the Internet and democracy, intellectual property, and technology law as it relates to commercial transactions.
Palfrey came to the Berkman Center from the law firm Ropes & Gray, where he worked on intellectual property, Internet law, and private equity transactions. He was a co-founder and a former officer of a venture-backed technology company. He also served as a Special Assistant at the U.S. Environmental Protection Agency during the Clinton administration. He serves on the Board of Directors of the Charles River Watershed Association.
Palfrey graduated from Harvard College, the University of Cambridge, and Harvard Law School. His awards include the Rotary Foundation Ambassadorial Scholar to the University of Cambridge and the U.S. EPA Gold Medal (highest national award). He is admitted to the New York and Massachusetts bars.
Dennis Panicali
Dennis L. Panicali, who is the Company's Chief Scientific Officer, founded Therion Biologics in 1991 and served as President and CEO for 11 years. He directs the scientific advancement and expansion of Therion's product pipeline. From 1986 to 1991, Dennis was Vice President of Product Development at Applied bioTechnology, Inc. (AbT). Dennis pioneered the development of poxvirus vectors for use in immune therapies and cancer research at the New York State Department of Health Centers for Laboratories and Research. Dennis holds a B.S. in Microbiology from the University of Connecticut and a Ph.D. in Cell and Molecular Biology from the Medical College of Georgia.
Mark Peterson
Mark Peterson is a director in Procter & Gamble's External Business Development organization and has responsibility for technology transfer (in and out) for P&G's Corporate Research and Development. His team leads P&G's commercial Connect + Develop effort to fulfill the company's stated goal of "Ésourcing 50% of its innovations from the outside." Mark also has responsibility to explore New Business Models that maximize value creation for P&G and its partners. This work includes, but is not limited to, taking equity positions in technology spin-outs and joint ventures.
Mark began his career with the company in 1977 as a Sales Representative in Commercial Products. Prior to moving into EBD, Mark ran the Supervalu Customer Team and the Canadian Customer Business Development organizations. In these roles, Mark was responsible for direct sales of up to $2.0 billion a year and organizations numbering 600.
Hans-Peter Pfleger
Hans-Peter Pfleger, Ph.D. is vice President, Global Strategic Eye Care for Allergan. He received both his Masters and Doctorate degrees in Chemistry from the University of Karlsruhe in Germany. He has over 23 years experience in the pharmaceutical industry, both in Europe and the United States. His current responsibilities include strategic planning, pre-launch and launch activities for new products and life-cycle management. He has been instrumental in several global product launches and life-cycle management programs.
Gene Potkay
Gene is VP Intellectual Property at Avaya and is responsible for managing and licensing Avaya's patent portfolio. From AT&T, its spin-off of Lucent Technologies and its subsequent spin-off of Avaya in Oct 2000,Êhe has a 15 year track recordÊof licensing and portfolio management experience. His career in telecom began in R&D for optical fiber technologiesÊas a Member of Technical Staff at Bell Laboratories starting with Western Electric's Engineering Research Center in Princeton, followed by R&D at Sandia National Laboratories Combustion Research Center and in area 11 at Bell Laboratories, Murray Hill. Gene holds a Ph.D in Engineering from Brown University, an M.S.M.E. from the University of Florida and a B.S.M.E. from the University of Massachusetts.
John Preston
Mr. Preston is President and CEO of Atomic Ordered Materials LLC., (AOM) and Senior Lecturer at the Massachusetts Institute of Technology. Before joining AOM, Mr. Preston was the Director of Technology Development (and Licensing) at M.I.T., where he was responsible for the commercialization of intellectual property developed at M.I.T. In this capacity he oversaw activities that led to the creation of over 250 new technology-based companies as well as the negotiation of thousands of licenses with existing companies. Many thousands of new jobs resulted from these license agreements. He also negotiated many complex agreements including the US standard for high definition television, while representing MIT on the HDTV Grand Alliance.
Mr. Preston is a Director of Clean Harbors Corporation as well as several privately owned companies.
Prior appointments include director or advisory positions for the Governor of Massachusetts, the US Department of Defense, the National Aeronautics and Space Administration, the National Science and Technology Board of Singapore and several others. Mr. Preston has testified seven times before the US Congress on issues related to technology commercialization and has chaired meetings on this subject for President George H. W. Bush and H.R.H. Prince Charles among others.
Mr. Preston received a Bachelors of Science in physics from the University of Wisconsin and a Masters of Business Administration from Northwestern University. He is the recipient of numerous awards and honors, including the Thomas Jefferson Award, given to the leading American in technology transfer and the Renaissance Engineering and Science Award from Stevens Institute of Technology. President Mitterand awarded Mr. Preston the rank of "Knight of the National Order of Merit" of France. Mr. Preston is also Honorary Alum of the Massachusetts Institute of Technology (only 131 such awards have been made by MIT is its 140 year history). Mr. Preston, in 1999, received the "Hammer Award" from Vice President Gore for reinventing Government. He was the only civilian to receive this award.
Arthur Rose
Mr. Rose has been a partner with the intellectual property law firm of Knobbe, Martens, Olson and Bear, LLP since 1984. Mr. Rose's practice areas include licensing of intellectual property rights, patent procurement and enforcement, securing and enforcing trademark rights, registering and enforcing copyright rights in computer programs and other works of authorship, identifying and enforcing trade secret rights, securing rights in domain names and dispute resolution in all areas of intellectual property law. Mr. Rose obtained his B.S. degree in Engineering with an Electronics concentration from the University of California, Los Angeles in 1974 and has significant experience assisting high technology, software and internet-based businesses build an intellectual property rights portfolio and defend against claims of infringement. Prior to joining Knobbe, Martens, Olson and Bear Mr. Rose worked as a Patent Examiner at the U.S. Patent and Trademark Office for four years. While working as a Patent Examiner Mr. Rose attended law school in the evenings, obtaining his law degree with honors from the George Washington University Law School in 1981. Immediately thereafter he worked as a law clerk for Judge Colaianni on the US Court of Claims. Mr. Rose is active in the Licensing Executives Society (USA/Canada) and is currently Vice President, Local Chapters, an International Delegate and a member of the LES Foundation Board. Mr. Rose has taught intellectual property law at UCI extension and has given several talks on intellectual property law topics including the preparation of development agreements and strategies for avoiding third party claims when launching a new product. Mr. Rose's technical areas of specialty include Electronics, Computers, Mechanical, Medical Devices and Procedures, Physics and Optics, Semiconductor Fabrication, Software, Internet, Data Processing and Telecommunications.
Edward Saltzman
Ed Saltzman is president of Defined Health, a leading strategic business development consulting firm to more than half of the top 20 pharmacos and many biotech, specialty pharma companies and healthcare investment firms. Prior to his 20+ years with Defined Health, Ed was responsible for evaluations and forecasting for licensing compounds at the Ayerst Laboratories unit of American Home Products, and he managed the Healthcare Information Center at FIND/SVP. Ed is a member of the Licensing Executives Society and the New York Pharma Forum, and is a frequent speaker on issues and dynamics affecting the Pharma-Biotech-Specialty Pharma industry complex.
Tom Sanchez
Tom graduated from Southern Illinois University in 1979 with a BSEE. Prior to university, Tom spent 3 years in the US Marine Corps as a field radio operator. After a brief stay at Rockwell working on the Space Shuttle Systems, Tom joined Motorola's Communications Sector in 1981 where he was employed as an R&D engineer developing transmitters for portable and mobile radio products.
Eventually, Tom joined what was to become Motorola's cellular handset business. During his tenure, Tom entered law school at Chicago Kent College of Law, completing the program through Motorola's educational program. He was admitted to the Bar in 1990. Initially, Tom's work in the cellular handset business was to develop and maintain a patent portfolio related to the nascent GSM products which Motorola was the first to deploy in volume for many years.
In 1990 Tom was given responsibility for implementing and negotiating the licenses to other handset manufacturers in the cellular business. He did so with the exception of a single agreement during the next 7 years. Tom continued in this role until 1997. Also during this time, and continuing later on, he was the Director of Standards for Motorola's handset businesses. In these capacities Tom reported to successive General Managers of Motorola's handset businesses; Tom insists the GM's were the real geniuses of the IPR operations and he learned much from them.
Recent significant court rulings in cellular patent cases have seen US federal courts take into consideration and parallel the licensing parameters set out in these early GSM licensing programs as being reasonable royalty guidelines for related cellular industry disputes.
Tom joined his present employer Research In Motion (RIM) in 2001. RIM is the maker of the BlackBerry wireless platform and products. He has been employed at RIM since joining them as Vice-President and Director of Licensing and Standards. He has successfully negotiated license agreements with the major holders of wireless related patents over the past two years. In addition, as at Motorola, Tom is responsible for the integration of RIM activities in public standards bodies and specification associations such as 3GPP.
Maria Sendra
Maria P. Sendra is a partner in Baker & McKenzie LLP's San Diego office and Chair of the Southern California Corporate and Securities Practice. Her practice focuses on corporate and strategic counseling of a variety of emerging growth and high technology companies. She has advised companies in the biotechnology, pharmaceutical, wireless, computer software and hardware, semiconductor, energy, entertainment, internet, and retail industries. Ms. Sendra has extensive experience with mergers and acquisitions, joint ventures and collaborations in research and development, manufacturing and international commercialization and distribution. She also has significant experience with initial public offerings and corporate financing, having represented both underwriters and issuers in the process. She frequently counsels public and private companies on the more intricate issues arising out of follow-on financings, SEC compliance, complex licensing, corporate alliances, and mergers and acquisitions strategies. Her acquisition and collaboration experience includes deals throughout the U.S, Europe and Asia. Ms. Sendra has published several articles on corporate joint ventures and global strategic alliances and has lectured as a keynote speaker for the UCLA Executive MBA program Distinguished Speaker Series, the Sa•d Business School at Oxford University, the UCSD Graduate School of International Relations and Pacific Studies on doing business in China, and the American Intellectual Property Law Association on innovative models for strategic alliances and investments. Ms. Sendra graduated with a B.A. magna cum laude from Yale University, has an M.A. with distinction from Indiana University, and a J.D. from the University of California at Berkeley where she was granted the Award for Excellence in Written Advocacy. She has a background in Molecular Biophysics and Biochemistry, ran a research lab while at Yale, and worked as a documentary filmmaker at Harvard University. She is fluent in Spanish, English, French and Valenciano and has studied German.
Zhu Shen
Dr. Zhu Shen is the CEO of BioForesight, Inc., a global life science strategic consulting company servicing its clients in Dealmaking/ Partnering, M&A Advisory, Private Equity & Debt Financing, Cross-Border Transactions, Corporate, Commercialization, and PR Strategy. Dr. Shen advises numerous clients/ organizations/ government officials on global partnering between Chinese life science entities with their overseas counterpart.
Dr. Shen has collaborated with several prominent life science conference organizers such as SRI, IBF, and CBI to create life science business conferences in Pharma/ Biotech Dealmaking/ Partnering, and Venture Investment.
Dr. Shen has been featured in interviews by "Wall Street Reporter" (WSR), "BayVoice", and "The Silicon Valley Times".
Dr. Shen has over 21 years of education and experience in medicine, biomedical research, and the business of life science. Prior to founding BioForesight, Inc., Dr. Shen worked at The Wilkerson Group; Bayer; and Chiron, with increasing responsibilities in marketing, new product strategic planning, corporate strategy, branding, and business/ corporate development.
Dr. Shen earned her Ph.D. in Biochemistry from University of Colorado, and her MBA from Cornell University's Johnson School of Management. She won the "Award for Outstanding Research" at the University of Colorado in 1993. She attended Peking University and Peking Union Medical College (PUMC) in China, the latter founded by the Rockefeller Foundation in 1917.
Jay Simon
After a long a long career with Exxon Mobil Corporation, Jay continued his activities in intellectual property law for a short period as counsel to the firm of Weil, Gotshal & Manges LLP. At Exxon Mobil, Jay held several positions rising from patent attorney to License Counsel and then Assistant General Counsel for Exxon Mobil Research and Engineering Company.
Jay is active in ADR, served on the arbitration committee of the Association of the Bar of the City of New York, and is now a panelist for implementing the Uniform Domain Name Dispute Resolution Policy, as well as serving as a WIPO arbitrator and mediator.
Jay holds a Bachelor of Chemical Engineering from the City College of New York, a Bachelor of Law and Masters of Law (Intellectual Property) from the New York University School of Law, and a certificate from the Parker School of International and Comparative Law at Columbia University Law School.
Jay is admitted to practice in the State of New York, is a registered attorney before the U.S. Patent and Trademark Office, and is admitted before the Court of Appeals for the Federal Circuit. He is a member of the New York State Bar Association, American Bar Association, American Intellectual Property Law Association, The Association of the Bar of the City of New York, and the Licensing Executives Society where he served on the Board of Trustees and as Vice-President.
Robin Sitver
Robin Sitver is Senior Director, Global Business Development and Strategic Planning for Pfizer Consumer Healthcare. She is responsible for global strategic planning and evaluation of strategic projects including divestitures for the over-the-counter consumer pharmaceutical business. She leads global business development efforts for eye care and new markets. She also directs the competitive intelligence function and serves as a member of the Corporate Business Intelligence team. She manages the market research effort to support licensing, acquisition, Rx-to-OTC switch and new category initiatives.
Robin joined Pfizer in 1979 in the Pharmaceuticals Division and held a variety of positions in finance, systems, marketing and international operations in the Pharmaceuticals and Animal Health Divisions before joining Pfizer Consumer Healthcare in 2001. She has been involved with numerous license, acquisition and divestiture transactions at Pfizer. She was the lead division finance person for the $1.45 billion acquisition of SmithKline Beecham Animal Health. Most recently, she negotiated the license and manufacturing agreements which led to the launches of Rolaids Softchews, Benadryl Fastmelts and Sudacare Vapor-Plugs within the last year.
Robin is an active member of the Licensing Executives Society. She was awarded the YMCA Woman Achiever of the Year Award in 1994. She is a member of the American Marketing Association. Robin is involved in numerous community activities and served on the Board of Trustees of the Zoological Society of New Jersey for 10 years.
Robin holds an MBA in Accounting and Decision Sciences from the Wharton School of the University of Pennsylvania and a BA in Computer Science from Brandeis University.
Larry Steranka
Larry Steranka is Executive Director of the Office of Intellectual Property and Technology Transfer at Brandeis University. Previously, he was Associate Director for Licensing in Harvard University's Office for Technology and Trademark Licensing and, before that, was director of the function at Vanderbilt University. Before entering academic technology transfer, Larry held research management positions in the pharmaceutical industry, first with a startup and then with a multinational company. Larry has a Ph.D. in pharmacology, completed one of Harvard Business School's Executive Education Programs (PMD), and is the author of over 40 peer-reviewed scientific publications.
Randall B. Sunberg
Randall B. Sunberg leads the life sciences transactions practice at Morgan Lewis, representing pharmaceutical, biotechnology and other life sciences companies in mergers and acquisitions, joint ventures, strategic alliances, collaborations and corporate partnering transactions. He graduated from New York University School of Law and Yale University.
Scott Swanson
Scott Swanson is the current Director of Global Business Intelligence for Oracle Corporation's CEO Office. There, his specialty is strategic and tactical intelligence focused on competitor's pricing and licensing practices. With over 10 years of competitive intelligence involvement, Mr. Swanson has worked for Big 5 management consultancies, operated a successful Executive Search and Research firm, and has done extensive Industrial Intelligence contracting. Scott's professional interests are in Intellectual Property containment and counterintelligence exercises.
Scott has a B.A. in Foreign Language from Illinois State University and a Certificate in Competitive Intelligence from Drexel University. He is currently finalizing a Strategic Intelligence graduate degree at the American Military University, and conducting research for a Post- 9/11 Indications and Warning threat analysis model. He may be contacted by telephone at 312-651-8001, or by email at scott.swanson@oracle.com.
Masau Takayanagi
Associate Director
General Manager
Intellectual Property Department
Mitsubishi Pharma Corporation
1969- Mitsubishi Chemical Industries, Ltd.
1976- Patent Attorney of Japan
1999- General Manager, Legal Dept, Mitsubishi-Tokyo Pharmaceuticals
2001- General Manager, Intellectual Property Dept., Mitsubishi Pharma
Director, Licensing Executive Society Japan
2002- General Manager, Product Strategy Dept., Mitsubishi Pharma
2003- General Manager, Intellectual Property Dept., Mitsubishi Pharma
2004- Vice Preside |
